We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Response to Vicriviroc in Treatment- Experienced Subjects, as Determined by an Enhanced-Sensitivity Coreceptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group A5211.
- Authors
Zhaohui Su; Gulick, Roy M.; Krambrink, Amy; Coakley, Eoin; Hughes, Michael D.; Dong Han; Flexner, Charles; Wilkin, Timothy J.; Skolnik, Paul R.; Greaves, Wayne L.; Kuritzkes, Daniel R.; Reeves, Jacqueline D.
- Abstract
The enhanced-sensitivity Trofile assay (Monogram Biosciences) was used to retest coreceptor use at both study screening and study entry for 118 treatment-experienced subjects in AIDS Clinical Trials Group A5211 who had CCR5-tropic (R5) virus detected by the original Trofile assay at study screening. Among 90 recipients of vicriviroc, a significantly (P < .001) greater mean reduction in HIV-1 RNA was observed in 72 subjects with R5 virus versus 15 subjects reclassified as having dual/mixed-tropic viruses at screening: -1.11 versus -0.09 log10 copies/mL at day 14 and -1.91 versus -0.57 log10 copies/mL at week 24, respectively. Results suggest that the enhanced-sensitivity assay is a better screening tool for determining patient eligibility for CCR5 antagonist therapy.
- Publication
Journal of Infectious Diseases, 2009, Vol 200, Issue 11, p1724
- ISSN
0022-1899
- Publication type
Academic Journal
- DOI
10.1086/648090